Second, high expression of the inhibitory NKG2A receptor on the NK cells of pediatric cancer patients provides a rational basis for evaluation of the NKG2A blocking antibody monalizumab,68 which has been successfully trialled in some adult cancers.69 The gene discussed is KLRC1; the disease is cancer.